ASX - By Stock
|
MSB |
Re:
MSB - A Question of Trust?
|
|
otherperspective
|
297 |
72K |
62 |
12/10/21 |
12/10/21 |
ASX - By Stock
|
297
|
72K
|
62
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
otherperspective
|
10K |
3.0M |
57 |
21/09/21 |
21/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
101 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
18K
|
6.9M
|
101
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
53 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
18K
|
6.9M
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
48 |
18/09/21 |
18/09/21 |
ASX - By Stock
|
18K
|
6.9M
|
48
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
otherperspective
|
10K |
3.0M |
80 |
16/09/21 |
16/09/21 |
ASX - By Stock
|
10K
|
3.0M
|
80
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
otherperspective
|
5.7K |
2.8M |
54 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
5.7K
|
2.8M
|
54
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
otherperspective
|
5.7K |
2.8M |
107 |
10/09/21 |
10/09/21 |
ASX - By Stock
|
5.7K
|
2.8M
|
107
|
|
ASX - By Stock
|
MSB |
Re:
FY22 - It's all to play for here!
|
|
otherperspective
|
145 |
42K |
90 |
03/09/21 |
03/09/21 |
ASX - By Stock
|
145
|
42K
|
90
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Appendix 4E and Annual Report to Shareholders
|
|
otherperspective
|
59 |
13K |
27 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
59
|
13K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
otherperspective
|
1.5K |
509K |
89 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
1.5K
|
509K
|
89
|
|
ASX - By Stock
|
MSB |
Re:
Moderated
|
|
otherperspective
|
1.5K |
509K |
107 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
1.5K
|
509K
|
107
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
20 |
17/08/21 |
17/08/21 |
ASX - By Stock
|
18K
|
6.9M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Growing Confidence on COVID-19 Application
|
|
otherperspective
|
344 |
101K |
27 |
16/08/21 |
16/08/21 |
ASX - By Stock
|
344
|
101K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Management Update
|
|
otherperspective
|
157 |
46K |
56 |
10/08/21 |
10/08/21 |
ASX - By Stock
|
157
|
46K
|
56
|
|
ASX - By Stock
|
MSB |
Re:
Another AFR Article - this time on the Angioblast deal
|
|
otherperspective
|
98 |
24K |
22 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
98
|
24K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Another AFR Article - this time on the Angioblast deal
|
|
otherperspective
|
98 |
24K |
47 |
27/07/21 |
27/07/21 |
ASX - By Stock
|
98
|
24K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID ARDS Trial Respiratory Outcomes Presented
|
|
otherperspective
|
163 |
61K |
37 |
16/07/21 |
16/07/21 |
ASX - By Stock
|
163
|
61K
|
37
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
otherperspective
|
10K |
3.0M |
64 |
16/07/21 |
16/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Q3 Financial Results Webcast
|
|
otherperspective
|
300 |
86K |
73 |
06/07/21 |
06/07/21 |
ASX - By Stock
|
300
|
86K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Q3 Financial Results Webcast
|
|
otherperspective
|
300 |
86K |
167 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
300
|
86K
|
167
|
|
ASX - By Stock
|
MSB |
Re:
Disclosure issues
|
|
otherperspective
|
101 |
26K |
69 |
05/05/21 |
05/05/21 |
ASX - By Stock
|
101
|
26K
|
69
|
|
ASX - By Stock
|
OCC |
Re:
Ann: CelGro Study Results Open Up New US Market Access Strategy
|
|
otherperspective
|
85 |
21K |
19 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
85
|
21K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
142 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
18K
|
6.9M
|
142
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
otherperspective
|
1.7K |
540K |
24 |
08/04/21 |
08/04/21 |
ASX - By Stock
|
1.7K
|
540K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
otherperspective
|
1.1K |
318K |
132 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
318K
|
132
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
71 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
18K
|
6.9M
|
71
|
|
ASX - By Stock
|
OCC |
Re:
Friday's options exercise no threat to share price - the opposite given expectations?
|
|
otherperspective
|
13 |
3.6K |
16 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
13
|
3.6K
|
16
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Receives First US CelGro Product Approval
|
|
otherperspective
|
198 |
77K |
12 |
19/01/21 |
19/01/21 |
ASX - By Stock
|
198
|
77K
|
12
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Receives First US CelGro Product Approval
|
|
otherperspective
|
198 |
77K |
22 |
14/01/21 |
14/01/21 |
ASX - By Stock
|
198
|
77K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
otherperspective
|
763 |
327K |
38 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
763
|
327K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
otherperspective
|
763 |
327K |
95 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
763
|
327K
|
95
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
otherperspective
|
763 |
327K |
121 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
763
|
327K
|
121
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
otherperspective
|
311 |
93K |
102 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
93K
|
102
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
otherperspective
|
311 |
93K |
86 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
311
|
93K
|
86
|
|
ASX - By Stock
|
MSB |
Re:
cap raise
|
|
otherperspective
|
80 |
24K |
74 |
06/01/21 |
06/01/21 |
ASX - By Stock
|
80
|
24K
|
74
|
|
ASX - By Stock
|
MSB |
Re:
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse
|
|
otherperspective
|
311 |
93K |
59 |
05/01/21 |
05/01/21 |
ASX - By Stock
|
311
|
93K
|
59
|
|
ASX - By Stock
|
MSB |
Re:
MPC-06-ID Phase 3 results countdown
|
|
otherperspective
|
273 |
141K |
73 |
01/01/21 |
01/01/21 |
ASX - By Stock
|
273
|
141K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Do you still think Mesoblast will be the next CSL?
|
|
otherperspective
|
155 |
67K |
53 |
31/12/20 |
31/12/20 |
ASX - By Stock
|
155
|
67K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Do you still think Mesoblast will be the next CSL?
|
|
otherperspective
|
155 |
67K |
138 |
30/12/20 |
30/12/20 |
ASX - By Stock
|
155
|
67K
|
138
|
|
ASX - By Stock
|
MSB |
Re:
CHF - The real phase 3 headlines
|
|
otherperspective
|
147 |
74K |
139 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
147
|
74K
|
139
|
|
ASX - By Stock
|
MSB Biotech |
Re:
Mergers and acquisitions
|
|
otherperspective
|
72 |
32K |
67 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
72
|
32K
|
67
|
|
ASX - By Stock
|
MSB Biotech |
Re:
Mergers and acquisitions
|
|
otherperspective
|
72 |
32K |
12 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
72
|
32K
|
12
|
|
ASX - By Stock
|
MSB Biotech |
Re:
Mergers and acquisitions
|
|
otherperspective
|
72 |
32K |
152 |
22/12/20 |
22/12/20 |
ASX - By Stock
|
72
|
32K
|
152
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
otherperspective
|
1.0K |
519K |
184 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
519K
|
184
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
otherperspective
|
1.0K |
421K |
99 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
421K
|
99
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
otherperspective
|
1.0K |
421K |
135 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
421K
|
135
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
|
|
otherperspective
|
139 |
72K |
180 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
139
|
72K
|
180
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
|
|
otherperspective
|
272 |
110K |
47 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
272
|
110K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
|
|
otherperspective
|
272 |
110K |
167 |
06/12/20 |
06/12/20 |
ASX - By Stock
|
272
|
110K
|
167
|
|